Clinical TrialJun 11, 2026, 04:01 AM
Oculis to Present Privosegtor PIONEER Registrational Trials at Summit
AI Summary
Oculis Holding AG announced an upcoming presentation at Clinical Trials at the Summit 2026, where its CEO will discuss Privosegtor's PIONEER registrational program. Privosegtor, a novel neuroprotective candidate for optic neuritis (ON) and other optic neuropathies, has received Breakthrough Therapy designation from the FDA and PRIME designation from the EMA. The company is advancing its late-stage development, supported by encouraging Phase 2 ACUITY data and key regulatory milestones, aiming to address significant unmet medical needs.
Key Highlights
- Oculis to present on Privosegtor at Clinical Trials at the Summit 2026 on June 13, 2026.
- CEO Riad Sherif, M.D., will discuss Privosegtor's PIONEER registrational trials for optic neuropathies.
- Privosegtor is a peptoid small molecule aiming to be the first neuroprotective therapy for optic neuritis (ON).
- Received FDA Breakthrough Therapy and EMA PRIME designations for ON, along with Orphan Drug status.
- PIONEER program includes two registrational trials for ON and one for non-arteritic anterior ischemic optic neuropathy (NAION).
- Positive Phase 2 ACUITY trial results showed improvements in visual function and anatomical preservation.
Price Impact
More from OCS